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Summary
Aims: Irritability has been described as a frequent adverse event in patients affected 
by epilepsy and treated with perampanel (PER), levetiracetam (LEV), and less fre-
quently with valproic acid (VPA). Since the questionnaire for irritability (I‐EPI) is a 
validated instrument to measure this psychiatric manifestation in patients affected 
by epilepsy, in this study we aimed at investigating the effect of PER as first add‐on 
therapy on I‐EPI. Moreover, we compared the effectiveness and I‐EPI scores ob-
tained at 12‐month follow‐up visits in patients treated by PER, LEV, or VPA in order 
to measure irritability as a consequence of these treatments.
Methods: We collected data from 17 patients treated by PER, 16 patients treated by 
LEV, and 16 patients under VPA treatment followed for 12 months. 
Results: We did not document significant changes of I‐EPI questionnaire between 
baseline and follow‐up in the PER group. As concerning the comparison of I‐EPI 
among PER, LEV, and VPA groups, we documented lower global scores in PER than 
both LEV (P < 0.05) and VPA (P < 0.05) groups. Moreover, patients under PER treat-
ment showed lower scores than LEV and VPA (P < 0.05) in I‐EPI items measuring the 
gentle personality, anxiety of having epileptic seizures in front of others, and irritabil-
ity in thinking that they can have an epileptic seizure.
Conclusions: This retrospective study described a stable and possibly lower degree 
of irritability in patients starting PER than LEV and VPA treatments, although we 
documented the comparable effectiveness of PER, LEV, and VPA as first add‐on 
treatments in patients affected by uncontrolled epileptic seizures. However, the 
small sample of patients included in this study and the absence of I‐EPI scores ob-
tained at baseline visits in LEV and VPA groups require further investigations to con-
firm this preliminary evidence.
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1  | INTRODUC TION
Patients affected by epilepsy not only have to manage epileptic at-
tacks but also comorbid medical and/or psychiatric problems.1 In the 
past years, literature focused on depression and anxiety as import-
ant factors for determining quality of life and daily stress in patients 
affected by epilepsy.2 However, behavioral problems, such as irrita-
bility, also affect patients with epilepsy. Irritability is a mental state 
of extreme sensitivity to any kind of stimulation, which can produce 
different physical and mental responses.3 In epilepsy, irritability is 
intended as a multidimensional construct, which can be measured by 
a specific and validated questionnaire (I‐EPI). It consists of 18 items 
measuring the possibility to feel irritability in different situations.4 
Several external factors may rouse irritability in patients affected 
by epilepsy, such as the stigma and social discriminations due to ep-
ileptic condition, the irregular and unpredictable nature of their sei-
zure, and the side effects of antiepileptic drugs (AEDs). Accordingly, 
several AEDs have shown irritability as a psychiatric side effect in 
patients affected by epilepsy.5-7 Valproic acid (VPA), levetiracetam 
(LEV), and perampanel (PER) are three drugs owing respectively, to 
the first, second, and third generation of AED. Although all the three 
drugs have been associated with the occurrence of irritability as side 
effect, VPA has been recently associated with significant less irrita-
bility than other AEDs, such as LEV.5
Briefly, PER was recently licensed for the treatment of focal 
and generalized epilepsies.8,9 It is a noncompetitive α-amino-3-hy-
droxy‐5‐methyl‐4‐isoxazole proprionic acid (AMPA) receptor antag-
onist demonstrated efficacious in focal and generalized seizures in 
randomized controlled trials and clinical real‐life studies.10-12 LEV is 
a widely used AED, featured by a high therapeutic index and wide 
margin of safety compared to other AEDs.13 VPA is one of the oldest 
AED, characterized by a significant efficacy in treating epileptic sei-
zures, but associated with several side effects.14 Taking into account 
the literature describing the real-life use of the aforementioned 
AEDs, on the one hand it has been described that PER is associated 
with the occurrence of irritability, which has been mainly observed 
at high doses and in patients with intellectual disability.15-17 On the 
other hand, LEV and VPA have been both described causing irritabil-
ity or psychiatric manifestations as side effects, frequently related to 
epileptic seizure control.5,6,18 As a special condition characterized by 
the resolution of ictal and inter-ictal epileptic discharges associated 
with the occurrence of psychiatric manifestations, the term “forced 
normalization” has been postulated, and this rare manifestation has 
been documented in patients treated by LEV or VPA.18,19
Hence, since less but increasing data about the real‐life use 
of PER treatment, also as first add‐on, have been published in the 
recent past,20,21 this retrospective observational study aimed at 
better describing the effectiveness of PER and its psychiatric side 
effects, focusing on irritability. On these bases, the primary ob-
jective of the present study was to measure irritability by using 
the I‐EPI questionnaire in patients affected by uncontrolled sei-
zures who start PER as first add‐on treatment at baseline and 
12-month follow-up visits. The second objective of this study was 
to compare I‐EPI questionnaire obtained at follow‐up in patients 
treated by PER, VPA, or LEV as first add‐on treatment in order to 
monitor irritability in all the three groups. Finally, we compared 
the effectiveness of these three AEDs used as first add‐on treat-
ments at the 12-month follow-up visit.
2  | METHODS
The present report is a retrospective observational study based on 
individual charts review of patients affected by uncontrolled sei-
zures and under approved monotherapies, who started LEV, VPA, 
or PER as first add‐on AEDs for better controlling their secondarily 
generalized seizures. Data were collected by the two centers partici-
pating to the study, the Epilepsy Centre of the University Hospital 
of Rome “Tor Vergata,” and the Epilepsy Centre of the San Paolo 
Hospital in Milan. The eligible patients were retrospectively selected 
among those receiving LEV, VPA, or PER as first add‐on therapy 
from September 2016 to June 2017 and followed for 12 months. 
Patients were classified according to the 1981 International League 
Against Epilepsy, which was in use when patients were diagnosed.22 
We collected and analyzed data considering the baseline visit in 
which the AED was proposed as first add‐on therapy and the follow-
ing visit at 12-month follow-up.23 We included patients who main-
tained PER, VPA, and LEV treatment for 12 months, excluding those 
who interrupted the treatment for major adverse events. Since the 
primary objective of the study was to measure irritability by using 
the I‐EPI questionnaire in patients affected by epilepsy starting PER 
as first add‐on therapy, exclusively in this group of patients the I‐EPI 
questionnaire score was achieved at baseline and follow‐up visits. 
Unfortunately, the I‐EPI questionnaire scores were obtained only at 
follow‐up visits in the VPA and LEV groups and used for the com-
parison among the three groups (PER vs LEV vs VPA). Considering 
the retrospective nature of the study, the following data were col-
lected: age, sex, time since epilepsy onset, etiology (symptomatic or 
cryptogenic epilepsy), history of psychiatric disorders, 1‐month total 
seizure count at baseline and 12 months after starting LEV, VPA, 
or PER, previous AED monotherapy, I‐EPI questionnaires scores at 
the 12-month follow-up visit. Titration was performed according to 
clinical practice for PER, VPA, and LEV. For the statistical analysis, 
we analyzed and compared these data among the three groups: (a) 
50% responder rate, defined as the percentage of patients obtain-
ing a minimum of ≥50% seizures reduction in seizures’ frequency 
compared to baseline, (b) seizure freedom (considered as absence of 
seizures between time points), (c) I‐EPI questionnaire scores.
The I‐Epi is a 18‐item self‐administered questionnaire. Patients 
have to rate their irritability level on a 6‐point likert scale format, 
ranging from “never” (1), “almost never” (2), “rarely” (3), “sometimes” 
(4), “often” (5) to “always” (6). The overall irritability score was ob-
tained by summing single domain scores and ranges from 18 to 108; 
higher numerical values reflect a higher severity of symptoms. The 
answers to question 3 were reversed in calculation of the overall 
scores.
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The 18 items of the I‐EPI questionnaire identified four main do-
mains related to irritability in patients affected by epilepsy: Physical 
Functioning, Verbal Functioning, Temperamental Functioning, and 
Epilepsy Functioning. Scores in each item and the global scores were 
compared among the three groups.
The statistical analysis was performed using commercial software 
Statistica 10.0 program, Statsoft Inc, Tulsa, OK, USA.24 Descriptive 
data were expressed as mean and standard deviation for quantita-
tive analyses. The one‐way analysis of variance (ANOVA) was used 
to compare descriptive data among the three groups and p value 
was set at P < 0.05 for statistical significance. The paired t test was 
used to compare I‐EPI data between baseline and follow‐up in PER 
group, and between patients in the PER group who were seizure‐
free and not seizure‐free at follow‐up. The Bonferroni correction 
was applied when appropriate. This study was approved by the local 
Ethics Committee of the University Hospital of Rome “Tor Vergata”.
3  | RESULTS
Forty‐nine patients affected by uncontrolled secondarily generalized 
seizures who started a first add‐on treatment with LEV, VPA, or PER 
were included in this retrospective analysis. No patient was affected 
by learning or intellectual disabilities. PER was administered as first 
add‐on AED in 17 patients, whereas 16 patients started LEV and 16 
patients started VPA as first add‐on AED (see Table 1). The three 
groups did not significantly differ in terms of demographic data; 
moreover, groups did not differ for seizures’ baseline frequency, dis-
ease duration, age of epilepsy onset, history of psychiatric disorders, 
and previous AEDs (see Table 1). Eleven patients treated with PER, 
eight patients treated with LEV, and 12 patients treated by VPA 
showed an unremarkable brain MRI and epilepsy was defined as 
cryptogenic; on the other hand, six PER patients, eight LEV patients, 
and four VPA patients were affected by symptomatic epilepsy since 
they showed brain MRI alterations. Finally, two PER, two LEV, and 
three VPA patients presented history of psychiatric diseases.
Analyzing data achieved at 12 months follow‐up among the 
three groups, we documented the similar efficacy of PER, LEV, and 
VPA considering seizure freedom or seizures reduction ≥50% (see 
Figure 1).
Considering I‐EPI questionnaires, comparing data obtained at 
baseline and follow‐up in PER patients we did not document signifi-
cant differences in the global score (48.43 ± 21.43 vs 44.47 ± 16.56, 
P > 0.05) and in the single items’ scores. Notably, comparing the 
I‐EPI total scores completed at follow‐up visits by all patients, we 
documented lower scores in PER group compared to both VPA and 
LEV groups (see Table 2). Moreover, the items 3, 15, and 18 (owing 
to “I have a gentle personality,” “I get anxious if I have an epileptic 
seizure in front of others,” and “I get very irritable thinking that i can 
have an epileptic seizure,” respectively) were lower at follow‐up in 
the PER group compared to both LEV and VPA groups (see Table 2). 
Finally, patients treated by PER showed lower scores than LEV in 
I‐EPI subitem 6 and 8, quantifying the possibility to raise the voice 
if somebody contradicts them (“if somebody contradicts me, I raise 
my voice”) and considering the belief that others attain success more 
quickly than them (“I believe that others attain success more quickly 
than I do”) (see Table 2). We also compared in the group of patients 
treated by PER the I‐EPI questionnaires obtained at the follow‐up 
LEV (n = 16) 
(mean±SD)
VPA (n = 16) 
(mean±SD)
PER (n = 17) 
(mean±SD) P Value
Age (years) 37.2 ± 10.2 31.9 ± 8.6 37.7 ± 18.5 NS
Sex 8F8M 10F6M 8F9M NS
Etiology 8 cryptogenic 8 
symptomatic
12 cryptogenic 4 
symptomatic
11 cryptogenic 
6 symptomatic
NS
Disease Duration 
(months)
19.6 ± 15.0 17.3 ± 12.7 15.1 ± 9.7 NS
History of 
Psychiatric 
Disorders
2/16 3/16 2/17 NS
Previous AED 
monotherapy
11 CBZ 3 LTG 1 
OXC 1 TPM
6 CBZ 4 TPM 2 
OXC 2 ZNS 2 
LTG
7 CBZ 4 ZNS 3 
OXC 2 LTG 1 
PB
NA
Seizures at baseline 
(per month)
2.1 ± 0.9 2.4 ± 3.5 3.2 ± 2.1 NS
Seizures at 
follow-up (per 
month)
0.7 ± 0.9 1.0 ± 1.9 1.0 ± 1.6 NS
AED Dose mg/daily 2000.0 ± 1028.7 806.7 ± 469.4 5.6 ± 2.1 NS
LEV, levetiracetam; VPA, valproic acid; PER; perampanel; f, female; m, male; SD, standard deviation; 
CBZ, carbamazepine; LTG, lamotrigine; OXC, oxcarbazepine; TPM, topiramate; ZNS, zonisamide; PB, 
phenobarbital; NA, not admitted; NS, not significant; AED, antiepileptic drug.
TA B L E  1   Demographic and clinical 
data of patients
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visit between seizure‐free and not seizure‐free patients, and we ex-
clusively documented the significance for the item 3 score of the 
I‐EPI questionnaire (see Table 3).
4  | DISCUSSION
The present retrospective observational study investigated the 
symptom of irritability in patients starting PER as first add‐on 
treatment for better controlling their drug‐resistant seizures, also 
compared to patients starting VPA and LEV as first add‐on AED. 
Moreover, we assessed the effectiveness of PER, LEV, and VPA 
after 12-month follow-up. The main result of this study was the 
unmodified I‐EPI questionnaire between baseline and follow‐up in 
patients affected by epilepsy who started PER as first add‐on AED. 
Next, at follow‐up I‐EPI scores were lower in the PER group com-
pared to both LEV and VPA groups. Considering the single items of 
the I‐EPI questionnaire, scores of items 3, 15, and 18 were lower in 
the PER group than VPA and LEV groups, thus documenting less irri-
tability in the personality trait and in social conditions of daily living 
in patients who were prescribed PER than VPA and LEV. Moreover, 
patients in the PER group also showed lower scores at I‐EPI items 6 
and 8 than LEV. Nevertheless, PER was not associated with signifi-
cant changes of I‐EPI questionnaire between baseline and follow‐up 
visits, it showed a comparable effectiveness to VPA and LEV at the 
12‐month follow‐up visit. In the study design, we hypothesize to use 
LEV and VPA as comparators of PER, since LEV may induce psy-
chiatric adverse events, whereas VPA is less frequently associated F I G U R E  1   Effectiveness data in LEV, PER, and VPA groups. 
(PER: perampanel; VPA: valproic acid; LEV: levetiracetam)
LEV (n = 16) 
(mean ± SD)
VPA (n = 16) 
(mean ± SD)
PER (n = 17) 
(mean ± SD) P Value
Item 1 2.7 ± 1.5 2.5 ± 1.5 2.2 ± 1.4 NS
Item 2 3.5 ± 1.5 3.0 ± 1.6 2.6 ± 1.3 NS
Item 3 4.5 ± 1.5 4.1 ± 1.6 2.6 ± 1.5 PER vs LEV < 0.01 
PER vs VPA < 0.01
Item 4 2.7 ± 1.2 3.1 ± 1.6 2.3 ± 1.4 NS
Item 5 2.0 ± 1.5 2.1 ± 1.5 1.7 ± 1.0 NS
Item 6 3.8 ± 1.0 3.7 ± 2.0 2.6 ± 1.2 PER vs LEV < 0.01
Item 7 3.4 ± 1.7 3.0 ± 1.6 2.9 ± 2.2 NS
Item 8 3.2 ± 1.8 3.0 ± 1.9 2.0 ± 1.5 PER vs LEV < 0.01
Item 9 3.6 ± 2.2 3.9 ± 1.6 3.8 ± 1.8 NS
Item 10 1.2 ± 0.6 1.9 ± 1.9 1.9 ± 1.6 NS
Item 11 2.7 ± 2.1 2.7 ± 1.8 1.8 ± 1.2 NS
Item 12 3.1 ± 2.2 3.7 ± 1.4 2.9 ± 2.0 NS
Item 13 3.2 ± 1.2 3.7 ± 1.6 2.6 ± 1.5 NS
Item 14 2.9 ± 1.7 3.4 ± 1.6 2.8 ± 1.5 NS
Item 15 4.3 ± 1.8 4.4 ± 1.5 2.3 ± 1.8 PER vs LEV < 0.01 
PER vs VPA <0.01
Item 16 2.4 ± 1.8 3.0 ± 1.7 3.0 ± 1.9 NS
Item 17 2.7 ± 1.7 2.9 ± 1.7 1.9 ± 1.3 NS
Item 18 4.0 ± 1.9 4.4 ± 1.7 2.5 ± 2.1 PER vs LEV < 0.01 
PER vs VPA < 0.01
Global 
Score
56.1 ± 16.5 58.4 ± 14.8 44.5 ± 16.6 PER vs LEV < 0.01 
PER vs VPA <0.01
LEV, levetiracetam; VPA, valproic acid; PER; perampanel; I‐EPI, questionnaire for irritability in epi-
lepsy; SD, standard deviation; NS, not significant.
TA B L E  2   I‐EPI questionnaire scores at 
follow-up visits
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with irritability as a psychiatric adverse event than other AEDs.5 
Hence, I‐EPI scores were collected in patients who were visited at 
12‐month after the prescription of PER, LEV, or VPA.
These findings may broaden our view about the need of mea-
suring irritability by using validated instruments, as I‐EPI question-
naire. In keeping with the results of this study, it is conceivable 
that PER may less frequently cause irritability at lower doses when 
used as first add-on treatment. This result concords with a previ-
ous report published by our group and describing a good toler-
ability profile of PER when used as first adjunctive treatment.20 
Furthermore, recent real‐life observations confirmed the tolera-
bility and effectiveness of PER also in highly drug‐resistant pa-
tients with different epilepsy syndromes.21 In agreement with this 
recent evidence, serious psychiatric adverse events were usually 
reported by patients with psychiatric comorbidities; moreover, it 
appeared much more evident that PER may be more efficacious in 
treating symptomatic epilepsy, as previously suggested consider-
ing the mechanism of action of the drug.21,25
Irritability is a psychiatric symptom occurring in almost 60% 
of patients affected by epilepsy.17 Several circumstances includ-
ing socioeconomic, demographic, and clinical factors may be cor-
related with irritability. Since it has negative effects on daily living, 
an instrument able to quantify and monitor this symptom has been 
validated and provided. The I‐EPI questionnaire represents a spe-
cific measure of irritability in clinical and research practice.4 We 
documented that PER did not change the I‐EPI questionnaire in 
our patients’ population. This finding may be also explained con-
sidering the evidence that irritability is usually more frequent in 
patients under three or more AEDs.4,17 Moreover, level of irrita-
bility is closely related to seizure control and with AED doses; in 
particular, a post hoc analysis of behavioral side effects related 
to PER clearly described that irritability could be dose‐dependent 
and more frequent in patients with previous history of psychiat-
ric disorders.17,26 Thereafter, the good effectiveness of PER and 
its use as first add‐on therapy in our experience can explain the 
stability of I‐EPI questionnaire scores and the lower level of irrita-
bility in PER patients compared to VPA and LEV patients. Notably, 
irritability is usually associated with psychiatric diseases 27 and the 
scarce presence of psychiatric comorbidities in our patients’ pop-
ulation may explain the low level of irritability found in the PER 
group. We also compared the subgroups of patients ‐month fol-
low‐up visit to patients treated by PER who continued to experien-
treated by PER and seizure‐free at the 12ce seizures at follow‐up, 
but we did not document significant differences between the two 
groups, although the trend in higher I‐EPI scores in patients who 
were seizure‐free at follow‐up. However, the small sample of pa-
tients did not permit to drive definitive evidence and further stud-
ies should be performed. Hence, the possible explanation of our 
findings could consist in the fact that PER was prescribed as first 
add‐on AED and the therapeutic dose was lower than the dose 
often reached in more refractory epileptic patients.8,28,29
Our study has several limitations: the retrospective design, which 
can imply a bias in patients’ selection; the relatively short observation 
period of 12 months; the small number of patients included, although 
the number of patients in the three groups was similar thus allowing 
a comparison with statistical significance. Finally, we can monitor the 
change in I‐EPI questionnaire exclusively in patients starting PER, since 
I‐EPI questionnaire was not administered at baseline in patients under 
VPA and LEV. However, this first clinical retrospective investigation 
comparing irritability at 12-month follow-up visits in patients under 
PER, VPA, or LEV as first add‐on AED proposes the possibility to mon-
itor irritability during clinical visits in the epilepsy centers in order to 
better measure this disabling symptom, which can also represent a psy-
chiatric adverse event in patients affected by epilepsy. Hence, our con-
clusions should be cautiously considered as a preliminary impression, 
which requires further validation from studies on larger populations.
5  | CONCLUSIONS
Although irritability is a frequent symptom in patients affected by 
epilepsy, it can be controlled in patients starting low doses of PER as 
first add‐on treatment for uncontrolled epileptic seizures. The pos-
sible positive influence of PER on irritability can also be explained by 
the good effectiveness demonstrated by the drug, which was com-
parable to that of VPA and LEV when used as first add‐on therapy. 
This preliminary evidence needs to be further confirmed by pro-
spective and controlled longitudinal studies.
TA B L E  3   I‐EPI questionnaire scores in PER subgroups
Seizure-free (n = 10) 
(mean±SD)
Not seizure-free 
(n = 7) (mean±SD) P Value
Item 1 2.1 ± 1.5 1.9 ± 1.4 NS
Item 2 2.8 ± 1.3 2.2 ± 1.2 NS
Item 3 3 ± 1.5 2.0 ± 1.2 0.03
Item 4 2.9 ± 1.5 1.9 ± 1.1 NS
Item 5 2.3 ± 1.3 1.6 ± 1.4 NS
Item 6 3.2 ± 1.5 2.7 ± 1.6 NS
Item 7 3.5 ± 2.3 3.1 ± 2.7 NS
Item 8 2.8 ± 2.4 2.4 ± 2.4 NS
Item 9 4.4 ± 2.1 4.2 ± 2.8 NS
Item 10 2.8 ± 3.0 2.7 ± 3.1 NS
Item 11 2.9 ± 3.0 2.6 ± 3.5 NS
Item 12 4.0 ± 3.3 3.6 ± 3.8 NS
Item 13 3.5 ± 3.5 3.9 ± 3.8 NS
Item 14 4.0 ± 3.7 3.9 ± 4.3 NS
Item 15 3.2 ± 4.1 4.2 ± 4.8 NS
Item 16 4.2 ± 4.4 4.6 ± 4.9 NS
Item 17 3.3 ± 4.8 3.7 ± 5.5 NS
Item 18 3.4 ± 5.1 5.0 ± 5.6 NS
Global 
Score
44.5 ± 17.0 40.1 ± 16.1 NS
PER; perampanel; I‐EPI, questionnaire for irritability in epilepsy; SD, 
standard deviation; NS, not significant.
     |  637LIGUORI et aL.
ACKNOWLEDG MENTS
This study was partially supported by a grant funded by EISAI 
Pharmaceuticals, Italy.
CONFLIC TS OF INTERE S T
Claudio Liguori has been a consultant and/or attended to scientific 
advisory board for Eisai. Dr. Fabio Placidi received Research Support 
from EISAI Pharmaceuticals. Dr. Francesca Izzi has been a consult-
ant and/or attended to scientific advisory board for Eisai. Nicola 
Biagio Mercuri, Martina Assogna, Katherine Turner and Maria Paola 
Canevini declare no conflict of interest or financial disclosures.
We confirm that we have read the Journal's position on issues in-
volved in ethical publication and affirm that this report is consistent 
with those guidelines.
ORCID
Claudio Liguori  https://orcid.org/0000-0003-2845-1332 
R E FE R E N C E S
 1. Liguori C, Izzi F, Manfredi N, Mercuri NB, Placidi F. Lacosamide 
may improve cognition in patients with focal epilepsy: epitrack to 
compare cognitive side effects of lacosamide and carbamazepine. 
Epilepsy Behav Case Rep. 2018;10:35-37.
 2. Kwon OY, Park SP. Depression and anxiety in people with epilepsy. 
J Clin Neurol. 2014;10(3):175‐188.
 3. Caprara GV, Barbanelli C, Comrey AL. A èersonological approach to 
the study of irritability and aggression. Pres Ind Diff. 1992;13:77-84.
 4. Piazzini A, Turner K, Edefonti V, Bravi F, Canevini MP; LICE 
Irritability Group, Ferraroni M. A new Italian instrument for the 
assessment of irritability in patients with epilepsy. Epilepsy Behav 
2011;21(3):275‐281.
 5. Chen B, Choi H, Hirsch LJ, et al. Psychiatric and behavioral side ef-
fects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav. 
2017;76:24-31.
 6. Shukla G, Gupta A, Agarwal P, Poornima S. Behavioral effects and 
somnolence due to levetiracetam versus oxcarbazepine ‐ a retro-
spective comparison study of North Indian patients with refractory 
epilepsy. Epilepsy Behav. 2016;64(Pt A):216‐218.
 7. Schmitz B. Effects of antiepileptic drugs on mood and behavior. 
Epilepsia. 2006;47(Suppl 2):28‐33.
 8. Brodie MJ, Stephen LJ. Prospective audit with adjunctive peram-
panel: preliminary observations in focal epilepsy. Epilepsy Behav. 
2016;54:100-103.
 9. Strzelczyk A, Willems LM, Willig S, Rosenow F, Bauer S. Perampanel 
in the treatment of focal and idiopathic generalized epilepsies and 
of status epilepticus. Expert Rev Clin Pharmacol. 2015;8(6):733‐740.
 10. Kwan P, Brodie MJ, Laurenza A, FitzGibbon H, Gidal BE. Analysis of 
pooled phase III trials of adjunctive perampanel for epilepsy: impact 
of mechanism of action and pharmacokinetics on clinical outcomes. 
Epilepsy Res. 2015;117:117-124.
 11. Steinhoff BJ, Bacher M, Bast T, et al. First clinical experiences 
with perampanel–the Kork experience in 74 patients. Epilepsia. 
2014;55(Suppl 1):16‐18.
 12. Trinka E, Steinhoff BJ, Nikanorova M, Brodie MJ. Perampanel for 
focal epilepsy: insights from early clinical experience. Acta Neurol 
Scand. 2016;133(3):160‐172.
 13. Klitgaard H, Matagne A, Gobert J, Wülfert E. Evidence for a unique 
profile of levetiracetam in rodent models of seizures and epilepsy. 
Eur J Pharmacol. 1998;353(2–3):191‐206.
 14. Tomson T, Battino D, Perucca E. Valproic acid after five decades of 
use in epilepsy: time to reconsider the indications of a time-hon-
oured drug. Lancet Neurol. 2016;15(2):210‐218.
 15. Ettinger AB, LoPresti A, Yang H, et al. Psychiatric and behav-
ioral adverse events in randomized clinical studies of the non-
competitive AMPA receptor antagonist perampanel. Epilepsia. 
2015;56(8):1252‐1263.
 16. Maurousset A, Limousin N, Praline J, Biberon J, Corcia P, De Toffol 
B. Adjunctive perampanel in refractory epilepsy: experience at ter-
tiary epilepsy care center in Tours. Epilepsy Behav. 2016;61:237-241.
 17. Kwon OY, Park SP. Interictal irritability and associated factors in ep-
ilepsy patients. Seizure. 2016;42:38-43.
 18. Pakalnis A, Drake ME Jr, John K, Kellum JB. Forced normalization. 
Acute psychosis after seizure control in seven patients. Arch Neurol. 
1987;44(3):289‐292.
 19. Anzellotti F, Franciotti R, Zhuzhuni H, D'Amico A, Thomas A, Onofrj 
M. Nonepileptic seizures under levetiracetam therapy: a case re-
port of forced normalization process. Neuropsychiatr Dis Treat. 
2014;10:959-964.
 20. Liguori C, Izzi F, Manfredi N, et al. Efficacy and tolerability of perampanel 
and levetiracetam as first add-on therapy in patients with epilepsy: a 
retrospective single center study. Epilepsy Behav. 2018;80:173-176.
 21. Morano A, Fattouch J, Albini M, et al. Perampanel as adjunctive 
therapy in highly refractory epilepsies: real-world data from an 
Italian tertiary care epilepsy centre. J Neurol Sci. 2018;390:67-74.
 22. Proposal for revised clinical and electroencephalographic classi-
fication of epileptic seizures. From the commission on classifica-
tion and terminology of the international league against epilepsy. 
Epilepsia 1981;22(4):489‐501.
 23. Liguori C, Romigi A, Placidi F, Sarpa MG, Mercuri NB, Izzi F. Effective 
treatment of nocturnal frontal lobe epilepsy with lacosamide: a re-
port of two cases. Sleep Med. 2016;23:121-122.
 24. Liguori C, Romigi A, Izzi F, et al. Complement system dysregulation 
in patients affected by idiopathic generalized epilepsy and the ef-
fect of antiepileptic treatment. Epilepsy Res. 2017;137:107-111.
 25. Di Bonaventura C, Labate A, Maschio M, Meletti S, Russo E. 
AMPA receptors and perampanel behind selected epilepsies: cur-
rent evidence and future perspectives. Expert Opin Pharmacother. 
2017;18(16):1751‐1764.
 26. Villanueva V, Garcés M, López‐González FJ, et al. Safety, efficacy and 
outcome-related factors of perampanel over 12 months in a real-
world setting: the FYDATA study. Epilepsy Res. 2016;126:201-210.
 27. Kanner AM, Kozak AM, Frey M. The use of sertraline in patients 
with epilepsy: is it safe? Epilepsy Behav. 2000;1(2):100‐105.
 28. Coyle H, Clough P, Cooper P, Mohanraj R. Clinical experience with 
perampanel: focus on psychiatric adverse effects. Epilepsy Behav. 
2014;41:193-196.
 29. Shah E, Reuber M, Goulding P, Flynn C, Delanty N, Kemp S. Clinical 
experience with adjunctive perampanel in adult patients with un-
controlled epilepsy: a UK and Ireland multicentre study. Seizure. 
2016;34:1-5.
How to cite this article: Liguori C, Turner K, Izzi F, et al. 
Preliminary evidence about irritability in patients with 
epilepsy treated by perampanel as first add-on therapy 
compared to levetiracetam and valproic acid. CNS Neurosci 
Ther. 2019;25:632–637. https://doi.org/10.1111/cns.13098
